Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new GeneChip® Human Transcriptome Array 2.0, the most comprehensive microarray available for alternative splicing detection. GenoSplice, a leader in genomic data analysis and alternative splicing, has developed a dedicated expression analysis solution, EASANA®, including analysis for Affymetrix’ microarrays, such as GeneChip® Exon 1.0 ST Array, GeneChip® Human Transcriptome Array 1.0, and the new GeneChip® Human Transcriptome Array 2.0. When combined with GenoSplice analysis services, these arrays provide the highest resolution profiling of the transcriptome available on a microarray at both the gene and exon level.
“As part of Affymetrix’ commitment to provide end-to-end solutions, we are enabling those without access to bioinformatics to utilize the most powerful microarrays ever developed for the interrogation of alternative splicing events. Now with so many options open to researchers, it is increasingly more important to provide tools that generate biologically relevant results, not just data,” commented Kevin Cannon, SVP – Expression Business Unit at Affymetrix.
“We’re pleased to work with Affymetrix to combine two very powerful tools, Affymetrix’ high resolution microarrays for gene expression profiling of transcript isoforms and GenoSplice’s proprietary transcriptome data analysis service, to help researchers save valuable time so they can focus on the biology instead of on analytical details,” said Marc Rajaud, Co-CEO of GenoSplice. “GeneChip® Human Transcriptome Array 2.0 increases accessibility to genomic research, resulting in new data that have to be interpreted to be useful. Collaborating with Affymetrix helps keep GenoSplice on the forefront of developing dedicated tools that streamline and simplify genomic data analysis.”
PLEASE NOTE: Affymetrix®, the Affymetrix logo, and GeneChip® trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.
Products mentioned in this release are For Research Use only. Not for diagnostic procedures.
SOURCE: Affymetrix, Inc.
GenoSplice develops and globally markets unique high level bioinformatics analysis services for genomics data. The company provides in-house innovative solutions for integrated genomics and is unique in offering user-friendly support and long-term relationship for all next generation sequencing and microarray platforms. Each client as each analysis is unique. GenoSplice services mainly concern differential gene expression, alternative splicing, miRNA, fusion transcript, epigenetics, SNP, CNV, translocation and proteomics data. Visit www.genosplice.com for additional information.
Affymetrix technologies are used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, and Singapore. eBioscience is headquartered in San Diego, California and has manufacturing facilities in San Diego and Vienna, Austria. Including eBioscience, the Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2011, and other SEC reports for subsequent quarterly periods.